1. Generics Bulletin
  2. >>Policy & Regulation

Off-Patent Industry Criticizes CMS’ Negotiated Price Drug List

The Biosimilars Forum And AAM Have Given Their Thoughts On The Negotiations

 
• By Urtė Fultinavičiūtė

Off-patent industry groups in the US have raised questions about why Stelara is included on the list and if CMS’ projection can match up with estimated savings that could be generated traditionally by generics and biosimilars.

hands holding question marks
• Source: Shutterstock

“The Biosimilars Forum is greatly concerned that the Centers for Medicare & Medicaid Services is misinterpreting the Biosimilar Special Rule of the Inflation Reduction Act,” commented the Forum’s executive director Juliana Reed, in response to the recently released list of ten drugs and their negotiated prices that will come into effect on 1 January 2026.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin